One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Issue Highlights page
doi : 10.1016/S0360-3016(23)08095-1
Volume 118, Issue 1, 1 January 2024, Pages A11-A13
Rectal Cancer Update: Which Treatment Effects Are the Least “Brutal�?
Andrzej P. Wojcieszynski, MD,* Michael D. Chuong, MD,y Maria Hawkins, MD,z Krishan R. Jethwa, MD,x Hyun Kim, MD,? Ann Raldow, MD,{ Nina N. Sanford, MD, # and Jeffrey R. Olsen, MD
doi : 10.1016/j.ijrobp.2023.08.012
Volume 118, Issue 1, 1 January 2024, Pages 1-7
Ignorance is Bliss? A Case of Incidental Discovery of ATM Mutation in Prostate Cancer
Andrew Tam, MD,* and Yun Rose Li, MD, PhD*,
doi : 10.1016/j.ijrobp.2023.09.033
Volume 118, Issue 1, 1 January 2024, Pages 8-9
“Likely Pathogenic Heterozygous ATM Gene Mutation�: Not Always What It Seems
doi : 10.1016/j.ijrobp.2023.10.029
Volume 118, Issue 1, 1 January 2024, Page 10
SABR Today . . . and Tomorrow?
doi : 10.1016/j.ijrobp.2023.10.013
Volume 118, Issue 1, 1 January 2024, Page 11
Withdraw or Deposit?
doi : 10.1016/j.ijrobp.2023.10.042
Volume 118, Issue 1, 1 January 2024, Pages 12-13
A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations
Balamurugan Vellayappan, MBBS, FRANZCR,* Mary Jane Lim-Fat, MD, MSc, FRCPC,y Rupesh Kotecha, MD,z Antonio De Salles, MD, PhD,x,? Laura Fariselli, MD,{ Marc Levivier, MD, PhD, # Lijun Ma, PhD,** Ian Paddick, MSc,yy Bruce E. Pollock, MD,zz Jean Regis, MD,xx Jason P. Sheehan, MD, PhD,?? John H. Suh, MD,{{ Shoji Yomo, MD, PhD, ## and Arjun Sahgal, MD, FRCPC***
doi : 10.1016/j.ijrobp.2023.07.015
Volume 118, Issue 1, 1 January 2024, Pages 14-28
Consensus Delineation Guidelines for Pelvic Lymph Node Radiation Therapy of Prostate Cancer: On Behalf of the Francophone Group of Urological Radiation Therapy (GFRU)
Olivier De Hertogh, MD,* Guillaume Le Bihan, MD,y Thomas Zilli, MD,z,x,? Samuel Palumbo, MD,{ Marjory Jolicoeur, MD, # Gilles Crehange, MD, PhD,** Talar Derashodian, MD, # Guilhem Roubaud, MD,yy Carl Salembier, MD,zz Stephane Supiot, MD, PhD,xx,?? Olivier Chapet, MD, PhD,{{ Verane Achard, MD,?,## and Paul Sargos, MD
doi : 10.1016/j.ijrobp.2023.07.020
Volume 118, Issue 1, 1 January 2024, Pages 29-40
Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study
Katharina Br€uck, MD, PhD,*,{ Richard P. Meijer,y Joost L. Boormans,z Lambertus A. Kiemeney,x,? J. Alfred Witjes,? Lisa M.C. van Hoogstraten,x,{ Michiel S. van der Heijden, # A. Rogier Donders,x Martine Franckena,** Carin A. Uyl de Groot,yy,zz Annemarie M. Leliveld,xx Katja K.H. Aben,x,{ and Maarten C.C.M. Hulshof
doi : 10.1016/j.ijrobp.2023.07.027
Volume 118, Issue 1, 1 January 2024, Pages 41-49
Bladder Preservation and Immunotherapy: Rebel Without A Cause?
Priyamvada Maitre, MD,*,y and Ananya Choudhury, PhD
doi : 10.1016/j.ijrobp.2023.07.023
Volume 118, Issue 1, 1 January 2024, Pages 50-51
Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial
Tamim Niazi, MD,** Abdenour Nabid, MD,y Talia Malagon, PhD,z Redouane Bettahar, MD,x Linda Vincent, MD,? Andre-Guy Martin, MD,{ Marjory Jolicoeur, MD, # Michael Yassa, MD,** Maroie Barkati, MD,yy Levon Igidbashian, MD,zz Boris Bahoric, MD,* Robert Archambault, MD,xx Hugo Villeneuve, MD,?? James Man Git Tsui, MD,{{ and Mohammed Mohiuddin, MD
doi : 10.1016/j.ijrobp.2023.05.014
Volume 118, Issue 1, 1 January 2024, Pages 52-62
A New Pos-SIB-ility for Prostate and Pelvic Nodal Radiation Therapy in High-Risk Localized Prostate Cancer
Scott C. Morgan, MD,*,y Chen Hu, MS, PhD,y and Robert T. Dess, MD
doi : 10.1016/j.ijrobp.2023.08.060
Volume 118, Issue 1, 1 January 2024, Pages 63-65
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate Cancer
Karol?na Menne Guricova, MSc,* Veerle Groen, MD,y Floris Pos, PhD,* Evelyn Monninkhof, PhD,z Sjoerd G. Elias, PhD,z Karin Haustermans, Prof.,x Robert J. Smeenk, PhD,k Jochem van der Voort van Zyp, PhD,y Cedric Draulans, PhD,x Sofie Isebaert, PhD,x Petra J. van Houdt, PhD,* Linda G.W. Kerkmeijer, PhD,y,k and Uulke A. van der Heide, Prof.*
doi : 10.1016/j.ijrobp.2023.07.044
Volume 118, Issue 1, 1 January 2024, Pages 66-73
Assessing the Feasibility of Using Artificial Intelligence–Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost With External Beam Radiation Therapy
James M.G. Tsui, MD, PhD,*,y Christopher E. Kehayias, PhD,* Jonathan E. Leeman, MD,* Paul L. Nguyen, MD, MBA,* Luke Peng, MD,* David D. Yang, MD,* Shalini Moningi, MD,* Neil Martin, MD,* Peter F. Orio, DO, MS,* Anthony V. D’Amico, MD, PhD,* Jeremy S. Bredfeldt, PhD,* Leslie K. Lee, MD,z Christian V. Guthier, PhD,* and Martin T. King, MD, PhD
doi : 10.1016/j.ijrobp.2023.07.029
Volume 118, Issue 1, 1 January 2024, Pages 74-84
A Dosimetric Correlation Between Radiation Dose to Bone and Reduction of Hemoglobin Levels After Radiation Therapy for Prostate Cancer
Jordan B. Fenlon, MD, Geoff Nelson, PhD, Kathlina M. Teague, MS, Savannah Coleman, MS, Dennis Shrieve, MD, PhD, and Jonathan Tward, MD, PhD
doi : 10.1016/j.ijrobp.2023.07.036
Volume 118, Issue 1, 1 January 2024, Pages 85-93
Association of Sarcopenia With Toxicity-Related Discontinuation of Adjuvant Endocrine Therapy in Women With Early-Stage Hormone Receptor–Positive Breast Cancer
Anurag Saraf, MD,* Ismail Tahir, MBBCH,y Bonnie Hu, BS,* Anna-Sophia W. Dietrich, BS,y P. Erik Tonnesen, BS,y Gregory C. Sharp, PhD,* Gayle Tillman, MD,* Eric J. Roeland, MD, FAAHPM,z Ryan D. Nipp, MD, MPH,x Amy Comander, MD,? Jeffery Peppercorn, MD, MPH,? Florian J. Fintelmann, MD,y and Rachel B. Jimenez, MD
doi : 10.1016/j.ijrobp.2023.07.018
Volume 118, Issue 1, 1 January 2024, Pages 94-103
Time to Reconsider the Role of Diagnostic Chest Computed Tomography in Early-Stage Breast Cancer?
Jean L. Wright, MD,* and Jose G. Bazan, MD, MS
doi : 10.1016/j.ijrobp.2023.07.032
Volume 118, Issue 1, 1 January 2024, Pages 104-106
Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Leila T. Tchelebi, MD,*,y Kathryn A. Winter, MS,z Ross A. Abrams, MD,x Howard P. Safran, MD,? William F. Regine, MD,{ Susan McNulty, MS, # Abraham Wu, MD,** Kevin L. Du, MD, PhD,yy Samantha A. Seaward, MD,zz Shelly X. Bian, MD,xx Raid Aljumaily, MD,?? Anand Shivnani, MD,{{ Jeanna L. Knoble, MD, ## Todd S. Crocenzi, MD,*** Thomas A. DiPetrillo, MD,yyy Kevin S. Roof, MD,zzz Christopher H. Crane, MD,xxx and Karyn A. Goodman, MD
doi : 10.1016/j.ijrobp.2023.08.014
Volume 118, Issue 1, 1 January 2024, Pages 107-114
Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial
Floris S. Verheij, BSc,* Dana M. Omer, MD,* Sabrina T. Lin, MS,y Jonathan B. Yuval, MD,* Hannah M. Thompson, MD,* Jin K. Kim, MD,* Sebastian C. Valdivieso, MD,z Li-Xuan Qin, PhD,y Abraham J. Wu, MD,x Leonard B. Saltz, MD,? and Julio Garcia-Aguilar, MD, PhD
doi : 10.1016/j.ijrobp.2023.07.043
Volume 118, Issue 1, 1 January 2024, Pages 115-123
Incident Atrial Fibrillation and Survival Outcomes in Esophageal Cancer following Radiotherapy
Eric D. Miller, MD, PhD,* Trudy Wu, MD,y Grant McKinley, MD,z Jeremy Slivnick, MD,z Avirup Guha, MBBS, MPH,x Xiaokui Mo, PhD,? Rahul Prasad, MD, MBA,* Vedat Yildiz, MS,? Dayssy Diaz, MD, MS,* Robert E. Merritt, MD,{ Kyle A. Perry, MD, # Ning Jin, MD,** Dinah Hodge, BS,z Michael Poliner, MD,z Sunnia Chen, MD,z John Gambril, MD,z James Stock, MD,z Jameson Wilbur, BS,z Jovan Pierre-Charles, BS,z Sanam M. Ghazi, MD,z Terence M. Williams, MD, PhD,yy Jose G. Bazan, MD, MS,* and Daniel Addison, MD
doi : 10.1016/j.ijrobp.2023.08.011
Volume 118, Issue 1, 1 January 2024, Pages 124-136
Determining the Minimal Clinically Important Difference of the Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire to Evaluate the Change in the Quality of Life of Patients With Pancreatic Cancer During Radiation Therapy
Isabella Zaniletti, PhD,* Heather J. Gunn, PhD,y Christopher L. Hallemeier, MD,z Brady Scott Laughlin, MD,x Todd R. Leavitt,? Michael G. Haddock, MD,z Kenneth W. Merrell, MD,z James L. Leenstra, MD,{ Byron C. May, MD, # Jonathan B. Ashman, MD, # and Todd A. DeWees, PhD**
doi : 10.1016/j.ijrobp.2023.08.009
Volume 118, Issue 1, 1 January 2024, Pages 137-141
Salivary Electrostimulation in the Treatment of Radiation Therapy–Induced Xerostomia (LEONIDAS-2): A Multicenter, Randomized, Double-Masked, Sham-Controlled, Phase 3 Trial
Valeria Mercadante, PhD,* Arwa Al Hamad, PhD,y James McCaul, PhD,z Christopher Nutting, PhD,x Kevin Harrington,x,k Dawn Carnell, MB, BS, BSc,{ Teresa Guerrero Urbano, PhD, # Nicholas Kalavrezos, FRCS (OMFS), FFD, MD,** Julie A. Barber, PhD,yy,zz Stephen R. Porter, PhD,* and Stefano Fedele, PhD
doi : 10.1016/j.ijrobp.2023.03.047
Volume 118, Issue 1, 1 January 2024, Pages 142-153
The Merits of a Well Planned and Conducted Negative Study
Avraham Eisbruch, MD
doi : 10.1016/j.ijrobp.2023.09.001
Volume 118, Issue 1, 1 January 2024, Pages 154-156
HYPORT: Phase 1 Study of 3-Week Hypofractionated Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma
Dominic H. Moon, MD,* Vladimir Avkshtol, MD,* Dat Vo, MD,* Chul Ahn, PhD,y Baran Sumer, MD,z Andrew T. Day, MD,z Brittny Tillman, MD,z Larry Myers, MD,z John Truelson, MD,z and David J. Sher, MD, MPH
doi : 10.1016/j.ijrobp.2023.06.010
Volume 118, Issue 1, 1 January 2024, Pages 157-164
Leave No Cancer Behind: The Conformal Hypofractionation Era and Head and Neck Cancer
Scott C. Lester, MD,* Dominic H. Moon, MD,y Samir H. Patel, MD,z Musaddiq J. Awan, MD,x and Richard L. Bakst, MD
doi : 10.1016/j.ijrobp.2023.07.028
Volume 118, Issue 1, 1 January 2024, Pages 165-168
Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01)
Tingting Xu, MD,*,y,z,x Chunying Shen, MD,*,y,z,x Xin Zhou, MD,*,y,z,x Lin Zhu, MD,*,y,z,x Jun Xiang, MD,? Yulong Wang, MD,? Yongxue Zhu, MD,? Xiayun He, MD,* ,y,z,x Hongmei Ying, MD,*,y,z,x Yu Wang, MD,? Qinghai Ji, MD,? Chaosu Hu, MD,*,y,z,x and Xueguan Lu, MD
doi : 10.1016/j.ijrobp.2023.07.037
Volume 118, Issue 1, 1 January 2024, Pages 169-178
Leveraging the Potential of Induction Therapy in Human Papillomavirus–Mediated Oropharyngeal Carcinoma
Ezra Hahn, MD,* and Shao Hui Huang, MD, MSc, MRT(T
doi : 10.1016/j.ijrobp.2023.09.035
Volume 118, Issue 1, 1 January 2024, Pages 179-181
Correlation of Hematological Parameters With Clinical Outcomes in Cervical Cancer Patients Treated With Radical Radio(chemo)therapy: A Retrospective Study
Amrendra Kumar, MD, * Lavanya Gurram, MD, * Pushpa Naga Ch, MD, y Prashant Nayak, MD, * Gargee Mulye, MD, * Supriya Chopra, MD, * Reena Engineer, MD, * Shyam Kishore Shrivastava, MD, z Sudeep Gupta, DM,x Jaya Ghosh, DM,x Seema Gulia, DM,x Jai Prakash Agarwal, MD, * and Umesh Mahantshetty, MD
doi : 10.1016/j.ijrobp.2023.07.022
Volume 118, Issue 1, 1 January 2024, Pages 182-191
Locoregional Treatment in Patients With Metastatic Cervical Cancer: Benefit of Dose Escalation Strategies
Adrien Laville, MD,* Kanta Ka, MD,* Radouane El-Ayachi, MD,* Samir Achkar, MD,* Sophie Bockel, MD,* Sebastien Gouy, PhD,y Sophie Espenel, MD,* Philippe Morice, PhD,y Roger Sun, PhD,* Patricia Pautier, PhD,z and Cyrus Chargari, PhD
doi : 10.1016/j.ijrobp.2023.07.046
Volume 118, Issue 1, 1 January 2024, Pages 192-202
Oncostatin M/Oncostatin M Receptor Signal Induces Radiation-Induced Heart Fibrosis by Regulating SMAD4 in Fibroblast
Peng Xu, MD,*,y,z Yali Yi, MD,*,y,z Le Xiong, MD,*,y,z Yuxi Luo, MD,*,y Caifeng Xie, PhD,x Daya Luo, PhD,x Zhimin Zeng, MD, PhD,* ,y,z and Anwen Liu, MD, PhD
doi : 10.1016/j.ijrobp.2023.07.033
Volume 118, Issue 1, 1 January 2024, Pages 203-217
Glycyrrhetinic Acid Mitigates Radiation-Induced Pulmonary Fibrosis via Inhibiting the Secretion of TGF-β1 by Treg Cells
Jinmei Chen, MS,*,y,z Caihong Wang, MS,* Xiaoxian Pan, MS,* Yuping Zhan, MS,* Weitong Zhou, MS,* Shaoli Peng, MS,* Chun Chen, PhD,x Mingwei Zhang, PhD,*,y,z Ruilong Lan, MS,y,? Jiandong Wu, BS,*,z Fei Huang, PhD,y,? and Jinsheng Hong, PhD
doi : 10.1016/j.ijrobp.2023.08.005
Volume 118, Issue 1, 1 January 2024, Pages 218-230
Quantifying the Effect of 4-Dimensional Computed Tomography–Based Deformable Dose Accumulation on Representing Radiation Damage for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Standard-Fractionated Intensity-Modulated Radiation Therapy
Yulun He, PhD,* ,y Guillaume Cazoulat, PhD,y Carol Wu, MD,z Stina Svensson, PhD,x Lusmeralis Almodovar-Abreu,y Bastien Rigaud, PhD,y Emma McCollum,y Christine Peterson, PhD,k Zachary Wooten,{ Dong Joo Rhee, PhD, # Peter Balter, PhD, # Julianne Pollard-Larkin, PhD, # Carlos Cardenas, PhD,** Laurence Court, PhD, # Zhongxing Liao, MD,yy Radhe Mohan, PhD,# and Kristy Brock, PhDy
doi : 10.1016/j.ijrobp.2023.07.016
Volume 118, Issue 1, 1 January 2024, Pages 231-241
Systematic Evaluation of the Impact of Lung Segmentation Methods on 4-Dimensional Computed Tomography Ventilation Imaging Using a Large Patient Database
Yingxuan Chen, PhD,* Soroush Heidari Pahlavian, PhD,y Paul Jacobs, MS, y Taindra Neupane, PhD,* Farnoush Forghani-Arani, PhD,z Edward Castillo, PhD,x Richard Castillo, PhD,k and Yevgeniy Vinogradskiy, PhD
doi : 10.1016/j.ijrobp.2023.08.017
Volume 118, Issue 1, 1 January 2024, Pages 242-252
Impact of Multiple Beams on the FLASH Effect in Soft Tissue and Skin in Mice
Anthony Mascia, PhD,*,y Shelby McCauley, MSc,* Joseph Speth, BSc,*,y Stefanno Alarcon Nunez, BSc,*,y Gael Boivin, MD, PhD,z Marta Vilalta, PhD,z Ricky A. Sharma, MA, MBBChir, FRCP, FRCR, PhD,z John P. Perentesis, MD, FAAP,z and Mathieu Sertorio, PhD
doi : 10.1016/j.ijrobp.2023.07.024
Volume 118, Issue 1, 1 January 2024, Pages 253-261
Proton and Electron Ultrahigh-Dose-Rate Isodose Irradiations Produce Differences in Reactive Oxygen Species Yields
William Thomas, MS,* Jacob Sunnerberg, BS,y Matthew Reed, BS,* David J. Gladstone, ScD,y,z Rongxiao Zhang, PhD,y,z Joseph Harms, PhD,x Harold M. Swartz, MD, MSPH, PhD,y,z and Brian W. Pogue, PhD
doi : 10.1016/j.ijrobp.2023.07.042
Volume 118, Issue 1, 1 January 2024, Pages 262-267
The Auto-Lindberg Project: Standardized Target Nomenclature in Radiation Oncology Enables Real-World Data Extraction From Radiation Treatment Plans
Andrew Hope, MD,*,y Jun Won Kim, MD, PhD,z Michal Kazmierski, MS,x Mattea Welch, PhD,k Joseph Marsilla, MS,x Shao Hui Huang, MD, MSc, MRT(T),* ,y Ali Hosni, MD, PhD,*,y Tony Tadic, PhD,*,y Tirth Patel, BSc,y Benjamin Haibe-Kains, PhD,{ John Waldron, MD,*,y Brian O’Sullivan, MD,*,y and Scott Bratman, MD, PhD
doi : 10.1016/j.ijrobp.2023.08.018
Volume 118, Issue 1, 1 January 2024, Pages 268-274
Dose-Volume Tolerance of the Brain and Predictors of Radiation Necrosis After 3-Fraction Radiosurgery for Brain Metastases: A Large Single-Institutional Analysis
Rituraj Upadhyay, MD,* Ahmet S. Ayan, PhD,y Sagarika Jain, PhD,y Brett G. Klamer, PhD,z Haley K. Perlow, MD,* Wesley Zoller, CMD,* Dukagjin M. Blakaj, MD, PhD,* Sasha Beyer, MD, PhD,* John Grecula, MD,* Andrea Arnett, MD,* Evan Thomas, MD, PhD,* Arnab Chakravarti, MD,* Raju R. Raval, MD, DPhil,* and Joshua D. Palmer, MD
doi : 10.1016/j.ijrobp.2023.07.040
Volume 118, Issue 1, 1 January 2024, Pages 275-284
68Ga-FAPI-04 Positron Emission Tomography Distinguishes Malignancy From 18F-FDG-Avid Colorectal Lesions
Chengfang Shangguan, PhD,* Chen Yang, PhD,y Zhaopeng Shi, PhD,z Ying Miao, MD,x Wangxi Hai, MS,x Yan Shen, MS,? Qing Qu, PhD,* Biao Li, PhD,x and Jun Mi, PhD
doi : 10.1016/j.ijrobp.2023.08.019
Volume 118, Issue 1, 1 January 2024, Pages 285-294
Application and Challenges of Statistical Process Control in Radiation Therapy Quality Assurance
Qing Xiao, MS,*,y and Guangjun Li, PhD*
doi : 10.1016/j.ijrobp.2023.08.020
Volume 118, Issue 1, 1 January 2024, Pages 295-305
In Regard to Kim et al.
doi : 10.1016/j.ijrobp.2023.08.007
Volume 118, Issue 1, 1 January 2024, Pages 306-308
In Reply to Liu and Luo
doi : 10.1016/j.ijrobp.2023.08.006
Volume 118, Issue 1, 1 January 2024, Pages 308-309
In Regard to Brück et al.
Kangpyo Kim, MD Yong Chan Ahn, MD, PhD
doi : 10.1016/j.ijrobp.2023.09.029
Volume 118, Issue 1, 1 January 2024, Pages 309-310
In Reply to Hasan et al.
doi : 10.1016/j.ijrobp.2023.09.028
Volume 118, Issue 1, 1 January 2024, Pages 310-311
2023 Multidisciplinary Thoracic Cancers Symposium: Committees and Awardees
doi : 10.1016/j.ijrobp.2023.10.078
Volume 118, Issue 1, 1 January 2024, Page e1
Stereotactic Radiation for Ultra-Central Non-Small Cell Lung Cancer: A Safety and Efficacy Trial (SUNSET)
doi : 10.1016/j.ijrobp.2023.10.049
Volume 118, Issue 1, 1 January 2024, Page e2
A Population-Based Analysis of the Management of Symptoms of Depression among Patients with Stage IV Non-Small Cell Lung Cancer in Ontario, Canada
doi : 10.1016/j.ijrobp.2023.10.050
Volume 118, Issue 1, 1 January 2024, Pages e2-e3
Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC)
doi : 10.1016/j.ijrobp.2023.10.051
Volume 118, Issue 1, 1 January 2024, Pages e3-e4
Lung Cancer Survival Trends in the Veterans Health Administration
doi : 10.1016/j.ijrobp.2023.10.052
Volume 118, Issue 1, 1 January 2024, Page e4
KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
doi : 10.1016/j.ijrobp.2023.10.053
Volume 118, Issue 1, 1 January 2024, Pages e4-e5
Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
doi : 10.1016/j.ijrobp.2023.10.054
Volume 118, Issue 1, 1 January 2024, Page e5
Esophagitis Following Intensity-Modulated Radiotherapy for Lung Cancer
doi : 10.1016/j.ijrobp.2023.10.056
Volume 118, Issue 1, 1 January 2024, Page e6
Efficacy and Safety of Immune Checkpoint Inhibitors (ICI) in Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
doi : 10.1016/j.ijrobp.2023.10.056
Volume 118, Issue 1, 1 January 2024, Page e6
Clinical, Quality of Life and Cost Outcomes in Patients with Early Stage Non Small Cell Lung Cancer Undergoing Surgery or SBRT
doi : 10.1016/j.ijrobp.2023.10.057
Volume 118, Issue 1, 1 January 2024, Pages e6-e7
Disparities in Delivery of Local-Consolidative Surgery for Patients with Single-Site Oligometastatic Non-Small Cell Lung Cancer
doi : 10.1016/j.ijrobp.2023.10.058
Volume 118, Issue 1, 1 January 2024, Page e7
Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
doi : 10.1016/j.ijrobp.2023.10.059
Volume 118, Issue 1, 1 January 2024, Pages e7-e8
The Keynote B36 (EF-36) Pilot Study of Tumor Treating Fields (TTFields) Therapy with pembrolizumab as First-Line Treatment of PD-L1-Positive, Advanced or Metastatic Non-Small Cell Lung Cancer
doi : 10.1016/j.ijrobp.2023.10.060
Volume 118, Issue 1, 1 January 2024, Page e8
A Prospective, Multi-Institutional Digital Health Pilot Study to Detect Pneumonitis Early in Patients with Stage III NSCLC on durvalumab Monitored Remotely: Findings from the ON TRAX Study
doi : 10.1016/j.ijrobp.2023.10.061
Volume 118, Issue 1, 1 January 2024, Pages e8-e9
Retrospective Study of Pancreatic Lesions and Deaths from Pancreatic Cancer in a Large Cohort of Low-Dose CT Screening for Lung Cancer
doi : 10.1016/j.ijrobp.2023.10.062
Volume 118, Issue 1, 1 January 2024, Page e9
Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study
doi : 10.1016/j.ijrobp.2023.10.063
Volume 118, Issue 1, 1 January 2024, Pages e9-e10
Targeted Therapy for Lung Cancer and Pancreatic Toxicity: Retrospective Study and Recommendations
doi : 10.1016/j.ijrobp.2023.10.064
Volume 118, Issue 1, 1 January 2024, Pages e10-e11
Implementation of an Early-Stage Lung Cancer Survivorship Clinic in a Comprehensive Cancer Center
doi : 10.1016/j.ijrobp.2023.10.065
Volume 118, Issue 1, 1 January 2024, Page e11
Real-World Outcomes of Stage III NSCLC Treated with Chemoradiation +/- durvalumab
doi : 10.1016/j.ijrobp.2023.10.066
Volume 118, Issue 1, 1 January 2024, Page e11
Impact of Effective Dose to Immune Cells (EDIC) in Early Stage NSCLC Treated with Lung SBRT
doi : 10.1016/j.ijrobp.2023.10.067
Volume 118, Issue 1, 1 January 2024, Pages e11-e12
Quantification of Radiotherapy-Induced Cardiac and Aortic Toxicity Using Magnetic Resonance Imaging in Lung cancer
doi : 10.1016/j.ijrobp.2023.10.068
Volume 118, Issue 1, 1 January 2024, Page e12
Mucosal Dose Constraints for Endoluminal High Dose Rate Brachytherapy for Esophageal Cancer
doi : 10.1016/j.ijrobp.2023.10.069
Volume 118, Issue 1, 1 January 2024, Pages e12-e13
Impact of Comorbidity Index on Clinical Outcome after Stereotactic Body Radiation Therapy in High-Risk Early-Stage Non-Small Cell Lung Cancer
doi : 10.1016/j.ijrobp.2023.10.071
Volume 118, Issue 1, 1 January 2024, Page e13
A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation
doi : 10.1016/j.ijrobp.2023.10.072
Volume 118, Issue 1, 1 January 2024, Pages e13-e14
KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC
doi : 10.1016/j.ijrobp.2023.10.073
Volume 118, Issue 1, 1 January 2024, Page e14
Risk Factors for Cardiac-Related Outcomes in Stage III Non-Small Cell Lung Cancer Patients
doi : 10.1016/j.ijrobp.2023.10.074
Volume 118, Issue 1, 1 January 2024, Pages e14-e15
SiCARIO: A Phase I/II Study of Split-Course Adaptive Radioimmunotherapy for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Adaptive Radiotherapy
doi : 10.1016/j.ijrobp.2023.10.075
Volume 118, Issue 1, 1 January 2024, Page e15
